COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #135 of 259
9/9 Late treatment study
Alamdari et al., Tohoku J. Exp. Med., 2020, 252, 73-84, doi:10.1620/tjem.252.73 (Peer Reviewed)
Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Source   PDF   Share   Tweet
Retrospective 459 patients in Iran 93% using HCQ, showing HCQ mortality RR 0.45, p = 0.028. HCQ was the only antiviral that showed a significant difference. Small number of control patients and subject to confounding by indication. Average admission delay 5.72 days.

Alamdari et al., 9/9/2020, retrospective, Iran, West Asia, peer-reviewed, 14 authors.
risk of death, 55.0% lower, RR 0.45, p = 0.03, treatment 427, control 32.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 259 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit